CNTA
Centessa Pharmaceuticals plc
NASDAQ · Healthcare · Biotechnology · GB
$40.50
+0.00%Year over year
Reported trailing growth
- Revenue
- -100.0%
- EBITDA
- -24.8%
- EBIT
- -31.1%
- EPS
- +1.7%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +47.9%
- EBITDA
- +17.4%
- EBIT
- -3.3%
- Net income
- +16.2%
- EPS
- +29.1%
- Free cash flow
- -36.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026